One evidence layer across teams

Support cross-functional teams with shared evidence workflows for strategy, science, reporting, and decision-making across the lifecycle.

Start free trial

From raw analysis to shared direction

See how EMET supports cross-functional teams working across strategy, science, reporting, and evidence interpretation.

Cross-functional capabilities

Explore a range of sample prompts and representative outputs from EMET across the workflows below.

Knowledge synthesis output summarizing TREM2 evidence, pipeline context, and unresolved scientific questions.

Literature & Knowledge Synthesis

Summarize the clinical and mechanistic evidence for targeting TREM2 in Alzheimer's disease. What are the key unresolved questions?

PubMedEurope PMCbioRxivKTMineSemantic Scholar
Competitive and IP intelligence output showing the KRAS G12C landscape across patents, trials, and readouts.

Competitive & IP Intelligence

Give me a competitive and IP landscape for KRAS G12C inhibitors - active trials, approved drugs, key patent holders, and upcoming data readouts.

KTMineClinicalTrials.govPubMedpreprints
Target and drug biology output showing mechanism, druggability, clinical assets, and safety context for CDK4.

Target & Drug Biology

Give me a full target profile for CDK4 - mechanism, tissue expression, druggability, known inhibitors with clinical data, and key safety considerations.

PharosOpen TargetsChEMBLUniProtDrugMechDB
Biomarker and genomics output showing variant-driven pharmacogenomic risk and dosing implications.

Biomarker & Genomics Science

What are the pharmacogenomic considerations for clopidogrel? Which patient populations are at risk of treatment failure, what variants drive this, and how should dosing be adjusted?

GWAS CataloggnomADClinVarPharmGKBPan-UKBB
Clinical trial science output showing accepted endpoints, active trial design patterns, and placebo benchmarks for MASH studies.

Clinical Trial Science & Evidence Interpretation

I am designing a Phase 2 trial in MASH (NASH). What endpoints are currently accepted by FDA and EMA, what are the active Phase 3 trials using, and what is the expected placebo response rate in histological endpoints?

ClinicalTrials.govPubMedDailyMedFDA review documents
Scientific communication output showing a forest plot and structured reporting assets for stakeholder review.

Scientific Communication & Structured Reporting

Build a forest plot comparing overall survival hazard ratios across the major PD-1/PD-L1 checkpoint inhibitor trials in first-line non-small cell lung cancer, and generate a slide deck summarizing the evidence for our medical affairs team.

Presentation builderSBGN diagramsKM curvesforest plots
Pathway and network analysis output highlighting biological processes driving treatment resistance.

Pathway & Network Analysis

I have a list of 50 genes upregulated in treatment-resistant breast cancer vs sensitive tumors from a DEG analysis. Run pathway enrichment and build the protein interaction network for the top hits. What biological processes are driving resistance?

ReactomeSTRINGGOKEGGBioGRID
Reports and dashboards output showing portfolio status, clinical evidence overlays, and competitive alerts.

Reports & Dashboards

Build a portfolio dashboard for our 8 oncology targets - pull the latest GO/NO-GO status from our internal assay tracker via API, overlay the published clinical evidence, and flag any targets where the competitive landscape has changed in the last 90 days.

pdf-report-generatorpowerpoint-presenterhtml-dashboardjupyter-notebooksbgn-diagram-generatorgenome-browserzotero-exportportfolio-view-builder
Visualization output showing a mutation lollipop plot annotated with domains and variant types.

Visualizations

Generate a mutation lollipop plot for TP53 in TCGA lung adenocarcinoma, annotated with functional domains and colored by variant type.

volcano-plotheatmappca-plotmanhattan-plotkaplan-meierforest-plotnetwork-viewermutation-lollipopadmet-radarcircos-plot

Frequently asked questions

Drug programs fail when biology is misunderstood. EMET exists to close that gap — before it closes your pipeline.

Start free trial